Trifluridine/tipiracil as a therapeutic option in real life setting of metastatic colorectal cancer: An efficacy and safety analysis
Background: In the phase III RECOURSE trial, the orally administered combination trifluridine/tipiracil (FTD/TPI) demonstrated a survival benefit and an acceptable safety profile, earning approval as a third-line therapy in metastatic colorectal cancer (mCRC). This study aimed to assess the efficacy...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2022-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_1c58b5c6047648c7be133e32cbf8bed0 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Daniel Sur |e author |
| 700 | 1 | 0 | |a Daniel Sur |e author |
| 700 | 1 | 0 | |a Cristina Lungulescu |e author |
| 700 | 1 | 0 | |a Ștefan Spînu |e author |
| 700 | 1 | 0 | |a Alecsandra Gorzo |e author |
| 700 | 1 | 0 | |a Elena-Adriana Dumitrescu |e author |
| 700 | 1 | 0 | |a Dan Ionut Gheonea |e author |
| 700 | 1 | 0 | |a Cristian-Virgil Lungulescu |e author |
| 245 | 0 | 0 | |a Trifluridine/tipiracil as a therapeutic option in real life setting of metastatic colorectal cancer: An efficacy and safety analysis |
| 260 | |b Frontiers Media S.A., |c 2022-10-01T00:00:00Z. | ||
| 500 | |a 1663-9812 | ||
| 500 | |a 10.3389/fphar.2022.1041927 | ||
| 520 | |a Background: In the phase III RECOURSE trial, the orally administered combination trifluridine/tipiracil (FTD/TPI) demonstrated a survival benefit and an acceptable safety profile, earning approval as a third-line therapy in metastatic colorectal cancer (mCRC). This study aimed to assess the efficacy and safety of FTD/TPI in daily clinical practice in Romanian population.Methods: A single-center, retrospective, and observational study analyzed patients with mCRC that received chemotherapy with trifluridine/tipiracil between May 2019 and May 2022 at the Oncology Institute Prof. Dr. Ion Chiricuță in Cluj-Napoca, Romania. Study endpoints included safety, and median progression-free survival (PFS).Results: In this Romanian cohort (n = 50) the most common treatment-emergent adverse event was haematological toxicity (76%): anemia (50%), leucopenia (38%), neutropenia (34%), and thrombocytopenia (30%), followed by fatigue (60%), and abdominal pain (18%). Overall, the median progression-free survival was 3.85 months (95% CI: 3.1-4.6 months). PFS was significantly correlated with the number of FTD/TPI administrations and prior surgery.Conclusion: Our study corroborated the previously described safety profile for FTD/TPI in the third-line setting, and demonstrated relatively superior mPFS. | ||
| 546 | |a EN | ||
| 690 | |a metastatic colorectal cancer | ||
| 690 | |a trifluridine/tipiracil | ||
| 690 | |a Romanian population | ||
| 690 | |a toxicity analysis | ||
| 690 | |a real-world data | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Frontiers in Pharmacology, Vol 13 (2022) | |
| 787 | 0 | |n https://www.frontiersin.org/articles/10.3389/fphar.2022.1041927/full | |
| 787 | 0 | |n https://doaj.org/toc/1663-9812 | |
| 856 | 4 | 1 | |u https://doaj.org/article/1c58b5c6047648c7be133e32cbf8bed0 |z Connect to this object online. |